Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503528 | 0.78 | TSHR (0.39) | TSHRMEN1KMT2AMAPTBTN3A1 | |
| SCHEMBL437879 | 0.77 | MEN1 (0.48) | MEN1KMT2ACYP1A2BACE1 | |
| SCHEMBL16503522 | 0.76 | TSHR (0.44) | TSHRMEN1KMT2AMAPTHPGD | |
| SCHEMBL16503510 | 0.76 | TSHR (0.44) | TSHRMEN1KMT2AMAPTHPGD | |
| SCHEMBL16503520 | 0.74 | KMT2A (0.39) | MEN1KMT2ACYP1A2BACE1 | |
| SCHEMBL7724629 | 0.74 | CYP1A2 (0.44) | TSHRMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7724626 | 0.74 | CYP1A2 (0.44) | TSHRMEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL16503526 | 0.72 | TSHR (0.47) | TSHRMEN1KMT2AMAPTHPGD | |
| SCHEMBL11899615 | 0.71 | CYP3A4 (0.38) | MEN1KMT2AMAPTCYP1A2HPGD | |
| SCHEMBL11899259 | 0.71 | MEN1 (0.36) | MEN1KMT2AMAPTCYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079869-B2 | Chiral disulfonimides | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STS, SUDS3, SF1 | TSHR 4279/4885MEN1 1578/4885KMT2A 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.